Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse

Burkitt leukemia/lymphoma (BL) and high-grade B-cell lymphoma (HGBL) have a high incidence of central nervous system (CNS) involvement, which is associated with poor prognosis. The hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen includes systemic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Samra, Bachar, Khoury, Joseph D., Morita, Kiyomi, Ravandi, Farhad, Richard-Carpentier, Guillaume, Short, Nicholas J., El Hussein, Siba, Thompson, Philip, Jain, Nitin, Kantarjian, Hagop, Jabbour, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945626/
https://www.ncbi.nlm.nih.gov/pubmed/34464974
http://dx.doi.org/10.1182/bloodadvances.2021004427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945626/
https://www.ncbi.nlm.nih.gov/pubmed/34464974
http://dx.doi.org/10.1182/bloodadvances.2021004427

Ejemplares similares